198 related articles for article (PubMed ID: 24676237)
1. [Antifungal susceptibility of clinical isolates of Scopulariopsis species].
Odero V; García-Agudo L; Guerrero I; Aznar P; García-Martos P; Rodríguez-Iglesias M
Rev Esp Quimioter; 2014 Mar; 27(1):17-21. PubMed ID: 24676237
[TBL] [Abstract][Full Text] [Related]
2. In vitro antifungal susceptibility of Scopulariopsis brevicaulis isolates.
Skóra M; Macura AB; Bulanda M
Med Mycol; 2014 Oct; 52(7):723-7. PubMed ID: 25049036
[TBL] [Abstract][Full Text] [Related]
3. In vitro antifungal susceptibility testing of Scopulariopsis brevicaulis strains using agar diffusion method.
Skóra M; Macura AB
Wiad Parazytol; 2011; 57(2):111-6. PubMed ID: 21682097
[TBL] [Abstract][Full Text] [Related]
4. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
6. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus species.
Skóra M; Bulanda M; Jagielski T
Antimicrob Agents Chemother; 2015 Sep; 59(9):5827-9. PubMed ID: 26100698
[TBL] [Abstract][Full Text] [Related]
8. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens.
Marangon FB; Miller D; Giaconi JA; Alfonso EC
Am J Ophthalmol; 2004 May; 137(5):820-5. PubMed ID: 15126145
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin and terbinafine against Scytalidium dimidiatum and Scytalidium hyalinum clinical isolates.
Lacroix C; de Chauvin MF
J Antimicrob Chemother; 2008 Apr; 61(4):835-7. PubMed ID: 18218642
[TBL] [Abstract][Full Text] [Related]
10. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
11. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.
Drogari-Apiranthitou M; Mantopoulou FD; Skiada A; Kanioura L; Grammatikou M; Vrioni G; Mitroussia-Ziouva A; Tsakris A; Petrikkos G
J Antimicrob Chemother; 2012 Aug; 67(8):1937-40. PubMed ID: 22535624
[TBL] [Abstract][Full Text] [Related]
12.
Maphanga TG; Britz E; Zulu TG; Mpembe RS; Naicker SD; Schwartz IS; Govender NP
J Clin Microbiol; 2017 Jun; 55(6):1812-1820. PubMed ID: 28356416
[TBL] [Abstract][Full Text] [Related]
13. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
14. [In vitro activities of posaconazole, fluconazole, itraconazole, ketoconazole and voriconazole against Candida glabrata].
Blanco MT; Cañadas J; García-Martos P; Marín P; García-Tapia A; Rodríguez J
Rev Esp Quimioter; 2009 Sep; 22(3):139-43. PubMed ID: 19662547
[TBL] [Abstract][Full Text] [Related]
15. [Antifungal susceptibility of Acremonium species using E-test and Sensititre].
Saldarreaga A; Garcia Martos P; Ruiz Aragón J; García Agudo L; Montes de Oca M; Puerto JL; Marín P
Rev Esp Quimioter; 2004 Mar; 17(1):44-7. PubMed ID: 15201923
[TBL] [Abstract][Full Text] [Related]
16. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
Fleck R; Dietz A; Hof H
J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.
Lei HL; Li LH; Chen WS; Song WN; He Y; Hu FY; Chen XJ; Cai WP; Tang XP
Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1099-1102. PubMed ID: 29536323
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
[TBL] [Abstract][Full Text] [Related]
20. Comparing Etest and Broth Microdilution for Antifungal Susceptibility Testing of the Most-Relevant Pathogenic Molds.
Lamoth F; Alexander BD
J Clin Microbiol; 2015 Oct; 53(10):3176-81. PubMed ID: 26202113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
